Free trade and economic collaboration as paradigms for access to medicines

Author(s):  
Olasupo Owoeye
2016 ◽  
Vol 1 (127) ◽  
pp. 116-127
Author(s):  
O. Lytvyn

This article deals with the prospects, possible risks and threats of deep and comprehensive free trade area («FTA+») between Ukraine and the EU. Features of foreign economic activity of Ukraine within the framework of FTA with the CIS are also considered in the article. A detailed analysis of the foreign trade statement and regional pattern of exports and imports of Ukraine is presented for the last few years. The key difference between «FTA+» with the EU and classic free trade areas is determined. Risks of the external economic collaboration of Ukraine with the European countries are described after intensifying of the conflict between Ukraine and Russian Federation. Reasons of suspension of the Free trade agreement between Russia and Ukraine are marked. It operated within the framework of FTA with the CIS, trade and economic collaboration between the countries until the abolition of a free trade with Ukraine by Russian Federation. The consequences of the European technical and phytosanitary standards, substantial diminishing of export and import duties and measures related to the preparation of internal market to «FTA+» are analysed for Ukraine. The form of «FTA+» is found out, which foresees the reduction and liquidation of trade barriers within the framework of a free trade regime. It doesn’t deal only with liberalization of bilateral commodity trade but such spheres, as: trade in services, regime of foreign direct investment, public purchasing and labour force movement. The form of «FTA+» also foresees a wide adaptation program of economic and sectoral legislation of Ukraine to the norms and standards of the EU that will allow removing of nontariff barriers for domestic exports to internal market of the EU.


2017 ◽  
Vol 48 (1) ◽  
pp. 1 ◽  
Author(s):  
Carlos Christopher Smith Diaz

The Trans-Pacific Partnership (TPP) is a multilateral free-trade agreement which New Zealand became a party to in 2016. This article focuses on the inconsistencies that arise between the language of the TPP and New Zealand law, with respect to data exclusivity regimes. Compliance with the TPP seems to entail an extension to the terms of data exclusivity for both biologics and small-molecule pharmaceuticals. This may have the effect of impeding access to medicines by delaying the entry of competition into the market. In particular the underlying rationale behind the biologic data exclusivity provisions appears to be the protection of American corporate profits rather than the stimulation of innovation or the long-term improvement of access to healthcare. As a result, these provisions are not in New Zealand's interest and if implemented into law they may be economically detrimental. 


2014 ◽  
Vol 52 (4) ◽  
pp. 1187-1189

Brian Davern Wright of the University of California, Berkeley reviews “Of Medicines and Markets: Intellectual Property and Human Rights in the Free Trade Era”, by Angelina Snodgrass Godoy. The Econlit abstract of this book begins: “Explores intellectual property and human rights in the free trade era. Discusses trading health for wealth; a primer on pharmaceutical intellectual property; market failures and fallacies; local politics, strange bedfellows, and the challenges of human rights mobilization; patient advocacy and access to medicines litigation; and writing globalization's rule book. Godoy is Helen H. Jackson Chair in Human Rights and Founding Director of the Center for Human Rights at the University of Washington.”


Sign in / Sign up

Export Citation Format

Share Document